Description
Approved accessible “nivolumab injection”
nivolumab injection was first approved in 2014. In 2022, CDER approved it to treat neoadjuvant (before surgery) non-small cel lung cancer. It is the first CDER-approved treatment for neoadjuvant lung cancer.
Nivolumab, is a medication used to treat a number of types of cancer. This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal junction (GEJ) cancer. It is used by slow injection into a vein. Nivolumab was approved for medical use in the United States in 2014. It is on the World Health Organization’s List of Essential Medicines. It is made using Chinese hamster ovary cells. Nivolumab is the second FDA-approved systemic therapy for mesothelioma and is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer.
How can 1 go about obtaining nivolumab injection?
If nivolumab injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
References
- FDA Approval Sought for Adjuvant Nivolumab for Completely Resected Stage IIB/C Melanoma
- FDA Accepts Supplemental BLA For Nivolumab For Melanoma
- FDA Drug Approvals, Pediatrics — 2022 Midyear Review
- FDA approves Opdivo-based combinations for esophageal squamous cell carcinoma